chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Pharmacist gave vaccine to 9 patients which looks like the lots were expired/ Expired vaccine used; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Pharmacist gave vaccine to 9 patients which looks like the lots were expired/ Expired vaccine used) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Pharmacist gave vaccine to 9 patients which looks like the lots were expired/ Expired vaccine used) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Pharmacist gave vaccine to 9 patients which looks like the lots were expired/ Expired vaccine used) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Pharmacist gave vaccine to 9 patients which looks like the lots were expired/ Expired vaccine used).    It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  It was reported that there were no specific dates when administration occurred, but they had the lot number, and it was before 13-Jul-2023 and Lot numbers were AS7165B, 020H22A, 021H22A, 017H22A. All vials were 5mL adult bivalent Moderna COVID-19 vaccine. The patients were fine. It was unknown when the vial was initially stored in the refrigerator. The vial did not underwent any temperature excursions. Unable to confirm what the date of first thaw was.  Dosage text for suspect product was reported as unknown.  No concomitant medications were provided. No treatment medication was provided.  This case contains information about patient 5th out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-734387 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2023: Follow up received, age group updated, event verbatim added  and I narrative have been updated; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-734387:Master case (Patient 1)
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Chills, Fatigue, Influenza like illness, Nausea, Pain
Clinical narrative: Achy; felt like she was getting the flu; Chills; some nausea; Patient did not sleep well; Her left injection site arm is still sore today/The patient had a sore arm; Patient was tired; This spontaneous case was reported by a patient and describes the occurrence of PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), POOR QUALITY SLEEP (Patient did not sleep well), VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) and FATIGUE (Patient was tired) in a 72-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. 019H22A and A571853) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 09-Nov-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 22-Jul-2023, received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. In July 2023, the patient experienced POOR QUALITY SLEEP (Patient did not sleep well), VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) and FATIGUE (Patient was tired). On an unknown date, the patient experienced PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), CHILLS (Chills) and NAUSEA (some nausea). At the time of the report, PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), CHILLS (Chills) and NAUSEA (some nausea) had resolved, POOR QUALITY SLEEP (Patient did not sleep well) and FATIGUE (Patient was tired) outcome was unknown and VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment information was reported.   This case was linked to MOD-2023-734471 (Patient Link).
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Poor quality sleep, Vaccination site pain
Clinical narrative: Achy; felt like she was getting the flu; Chills; some nausea; Patient did not sleep well; Her left injection site arm is still sore today/The patient had a sore arm; Patient was tired; This spontaneous case was reported by a patient and describes the occurrence of PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), POOR QUALITY SLEEP (Patient did not sleep well), VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) and FATIGUE (Patient was tired) in a 72-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. 019H22A and A571853) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 09-Nov-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 22-Jul-2023, received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. In July 2023, the patient experienced POOR QUALITY SLEEP (Patient did not sleep well), VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) and FATIGUE (Patient was tired). On an unknown date, the patient experienced PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), CHILLS (Chills) and NAUSEA (some nausea). At the time of the report, PAIN (Achy), INFLUENZA LIKE ILLNESS (felt like she was getting the flu), CHILLS (Chills) and NAUSEA (some nausea) had resolved, POOR QUALITY SLEEP (Patient did not sleep well) and FATIGUE (Patient was tired) outcome was unknown and VACCINATION SITE PAIN (Her left injection site arm is still sore today/The patient had a sore arm) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment information was reported.   This case was linked to MOD-2023-734471 (Patient Link).
Sex: U
Vaccine: COVID19-2
Symptoms: Autoimmune disorder, Vaccination site reaction
Clinical narrative: I am suffering from auto immune deficiency disease; The arm in which my vaccine was given became magnetic and remained this way for about 4months; This spontaneous case was reported by a patient and describes the occurrence of AUTOIMMUNE DISORDER (I am suffering from auto immune deficiency disease) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced AUTOIMMUNE DISORDER (I am suffering from auto immune deficiency disease) (seriousness criterion medically significant) and VACCINATION SITE REACTION (The arm in which my vaccine was given became magnetic and remained this way for about 4months). At the time of the report, AUTOIMMUNE DISORDER (I am suffering from auto immune deficiency disease) and VACCINATION SITE REACTION (The arm in which my vaccine was given became magnetic and remained this way for about 4months) outcome was unknown.            Patient was not magnetic before received the vaccine Patient was totally healthy before and when received  two jabs from moderna and now had been told that suffering from an auto immune deficiency disease. Concomitant medications were not reported.  No treatment information was provided by the reporter.  Company Comment: This is a spontaneous case concerning a patient of unknown age and gender, with no reported medical history, who experienced the serious (due to medically significant) unexpected, event of Autoimmune disorder, which occurred after the mRNA-1273.222 (Original/Omicron BA.4/5) vaccine, received as part of COVID-19 vaccination schedule, dose number not provided. Temporal association cannot be assessed due to lack of information on onset date of the event and vaccination date. The outcome was not reported. No further clinical information was available for medical review. The benefit-risk relationship of mRNA-1273.222 (Original/Omicron BA.4/5) vaccine is not affected by this report.    This case was linked to US-MODERNATX, INC.-MOD-2023-734384 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2023: Live follow-up include no new information; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-734384:
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19
Clinical narrative: she got sick with COVID after the last booster.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (she got sick with COVID after the last booster.) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (she got sick with COVID after the last booster.). At the time of the report, COVID-19 (she got sick with COVID after the last booster.) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. The patient had 1 initial vaccine and 3 boosters. No treatment medication was reported.   Reporter did not allow further contact
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Illness, Nausea
Clinical narrative: The patient got very sick/Patient was in bed sick; Achy; Diarrhea; Headache; Chills; Feverish; Vomited; Nausea; This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache) and CHILLS (Chills) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 012M20A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache), CHILLS (Chills), PYREXIA (Feverish), VOMITING (Vomited) and NAUSEA (Nausea). At the time of the report, ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache), CHILLS (Chills), PYREXIA (Feverish), VOMITING (Vomited) and NAUSEA (Nausea) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment information was reported.   This case was linked to MOD-2023-734507 (Patient Link).
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vomiting
Clinical narrative: The patient got very sick/Patient was in bed sick; Achy; Diarrhea; Headache; Chills; Feverish; Vomited; Nausea; This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache) and CHILLS (Chills) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 012M20A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache), CHILLS (Chills), PYREXIA (Feverish), VOMITING (Vomited) and NAUSEA (Nausea). At the time of the report, ILLNESS (The patient got very sick/Patient was in bed sick), PAIN (Achy), DIARRHOEA (Diarrhea), HEADACHE (Headache), CHILLS (Chills), PYREXIA (Feverish), VOMITING (Vomited) and NAUSEA (Nausea) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment information was reported.   This case was linked to MOD-2023-734507 (Patient Link).
Age: 84.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, COVID-19, Cachexia, Chronic obstructive pulmonary disease, Computerised tomogram thorax abnormal
Clinical narrative: Patient is a 85 y.o. male patient of a DO pmh copd, htn who presents to ED with cough and shortness of breath for the past 3 weeks   Acute deliriumresolved Alert awake oriented x 3 now Discussed with nursing staff to implement delirium precautions Continue clinical monitoring   Acute respiratory failure with hypoxia and hypercapnia, stable Acute exacerbation of copd>resolved Will need 2L O2 with activity Compelte decadron outpatient Pcp follow up   Covid-19 infection Date of onset of symptoms: 5/22/23 per patient Symptoms present on admission: cough, shortness of breath Date of covid positive test: 6/12/23 Vaccination status: fully vaccinated per patient Imaging: 6/12/23 CT without infi Imaging: 6/12/23 CT without infiltrates Oxygen requirements on admission: 2LNC Current oxygen requirements: 2 L nasal cannula Medical therapy: dexamethasone, ID consultedappreciate input.  Patient is not a candidate for remdesivir or Tocilizumab Consultants following: ID consulted Anticipated special isolation end date: 6/22   Essential htn Continue amlodipine    Iron deficiency anemia Started oral ferrous sulfate>continue  Seizure disorder  Continue phenytoin.    Cachexia Moderate protein-calorie malnutrition, POA Bmi 17.33 Continue oral nutritional supplementation   Left lung nodule Incidental findingnoted on CT Follow-up CT chest in 3 months
Age: 84.0
Sex: M
Vaccine: COVID19-2
Symptoms: Condition aggravated, Cough, Delirium, Dyspnoea, Malnutrition
Clinical narrative: Patient is a 85 y.o. male patient of a DO pmh copd, htn who presents to ED with cough and shortness of breath for the past 3 weeks   Acute deliriumresolved Alert awake oriented x 3 now Discussed with nursing staff to implement delirium precautions Continue clinical monitoring   Acute respiratory failure with hypoxia and hypercapnia, stable Acute exacerbation of copd>resolved Will need 2L O2 with activity Compelte decadron outpatient Pcp follow up   Covid-19 infection Date of onset of symptoms: 5/22/23 per patient Symptoms present on admission: cough, shortness of breath Date of covid positive test: 6/12/23 Vaccination status: fully vaccinated per patient Imaging: 6/12/23 CT without infi Imaging: 6/12/23 CT without infiltrates Oxygen requirements on admission: 2LNC Current oxygen requirements: 2 L nasal cannula Medical therapy: dexamethasone, ID consultedappreciate input.  Patient is not a candidate for remdesivir or Tocilizumab Consultants following: ID consulted Anticipated special isolation end date: 6/22   Essential htn Continue amlodipine    Iron deficiency anemia Started oral ferrous sulfate>continue  Seizure disorder  Continue phenytoin.    Cachexia Moderate protein-calorie malnutrition, POA Bmi 17.33 Continue oral nutritional supplementation   Left lung nodule Incidental findingnoted on CT Follow-up CT chest in 3 months
Age: 84.0
Sex: M
Vaccine: COVID19-2
Symptoms: Nutritional supplementation, Pulmonary mass, Respiratory failure, SARS-CoV-2 test positive
Clinical narrative: Patient is a 85 y.o. male patient of a DO pmh copd, htn who presents to ED with cough and shortness of breath for the past 3 weeks   Acute deliriumresolved Alert awake oriented x 3 now Discussed with nursing staff to implement delirium precautions Continue clinical monitoring   Acute respiratory failure with hypoxia and hypercapnia, stable Acute exacerbation of copd>resolved Will need 2L O2 with activity Compelte decadron outpatient Pcp follow up   Covid-19 infection Date of onset of symptoms: 5/22/23 per patient Symptoms present on admission: cough, shortness of breath Date of covid positive test: 6/12/23 Vaccination status: fully vaccinated per patient Imaging: 6/12/23 CT without infi Imaging: 6/12/23 CT without infiltrates Oxygen requirements on admission: 2LNC Current oxygen requirements: 2 L nasal cannula Medical therapy: dexamethasone, ID consultedappreciate input.  Patient is not a candidate for remdesivir or Tocilizumab Consultants following: ID consulted Anticipated special isolation end date: 6/22   Essential htn Continue amlodipine    Iron deficiency anemia Started oral ferrous sulfate>continue  Seizure disorder  Continue phenytoin.    Cachexia Moderate protein-calorie malnutrition, POA Bmi 17.33 Continue oral nutritional supplementation   Left lung nodule Incidental findingnoted on CT Follow-up CT chest in 3 months
Age: 18.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine BUD
Age: 18.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine BUD
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine BUD
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine BUD
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 80.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 80.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 25.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 25.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 29.0
Sex: M
Vaccine: UNK, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient receive vaccine after BUD
Age: 29.0
Sex: M
Vaccine: UNK, COVID19
Symptoms: Product storage error
Clinical narrative: Patient receive vaccine after BUD
Age: 7.0
Sex: M
Vaccine: COVID19-2
Symptoms: Product preparation error
Clinical narrative: PT WAS GIVEN VACCINE WITHOT ABEING DILUTED  PT HAD NO SIDE AFFECT AT TIME OF VACCINE
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema
Clinical narrative: pt said her arm is red around the site
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 25.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine after BUD
Age: 25.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine after BUD
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 86.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 86.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 51.0
Sex: M
Vaccine: COVID19-2
Symptoms: Dizziness postural
Clinical narrative: On 7/28/2023 at approximately 1:00 PM, client requested Pfizer Bivalent COVID-19 vaccine from the team nurses. The team nurse, PHN, RN asked client for demographic information and confirmed client's immunization record and vaccine eligibility in the electronic database. Upon assessment by the PHN, RN, client denied having any cardiac issues and reported allergies to penicillin, reaction unknown. Client reported a history Anxiety and he receives an intramuscular injection every month for Schizophrenia. Client reported he sees a Dr. at a local clinic for primary care. Client denied experiencing signs and symptoms of illness or dizziness today. PHN, RN completed the screening checklist for COVID 19 vaccine per CDC interim guidelines. At 1:00 PM, a second PHN, administered Pfizer Bivalent Vaccine lot # GM1767 intramuscularly in the left deltoid. At 1:02 PM client quickly stood up from his chair and stated he "feels dizzy." The second PHN, assisted client to sit down in the chair. Client stated he "felt better" after returning to a sitting position. Client took sips of water from his own water bottle. Client denied having blurry vision and denied nausea. Client did not appear diaphoretic and skin appeared dry and appropriate to ethnicity. Client alert and oriented to person, time, place, and situation. The second PHN, asked and received client's consent to take his vital signs at 1:05 PM while sitting: BP 130/88, Sp02 95%, HR 103 bpm, RR 18. The second PHN, gave client juice to drink. At 1:07 PM client denied feeling itchy, denied pain, and no redness or rash was observed by both PHNs. Client verbalized his dizziness was gone and had not returned. At 1:10 PM the second PHN, asked and received client's consent to take his vital signs: BP 124/90, SpO2 95%, HR 95 bpm, RR 20. Client denied any history of high blood pressure. At 1:15 PM the second PHN, assisted client to stand up. Client denied any dizziness or blurry vision or nausea. Client consented to the second PHN, taking vital signs again at this time: BP 126/88 SPO2 96% HR 95 bpm, RR 20. Client returned to sitting position and completed the rest of his observation time. Client walked away with stead gait and balance at 1:30 PM.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine past BUD
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine past BUD
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 42.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 42.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 0.58
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Given booster dose instead of primary dose
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine past BUD
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: Given booster dose instead of primary dose
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received vaccine after BUD
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Patient received vaccine after BUD
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD.
Age: 2.0
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine past BUD
Age: 4.0
Sex: F
Vaccine: DTAPIPVHIB, HEPA, PNC15, VARCEL
Symptoms: Injection site oedema, Injection site papule, Injection site pruritus, Injection site urticaria
Clinical narrative: Within minutes of receiving Pentacel and Varicella in left arm, child developed localized urticaria---pink papules and confluence and edema near sites of injections to left arm. (+) pruritus. No trouble breathing. No trouble swallowing. No lip or tongue swelling. Diphenhydramine (12.5mg/5mL) 10 mL provided. Called family that evening at ~7:30 pm and child was doing well with resolution of rash.  Vaccines were given the afternoon of 7/27 at ~3:30 pm.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 0.5
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine past BUD
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: Received vaccine past BUD
Age: 0.75
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Alanine aminotransferase, Anion gap, Aspartate aminotransferase, Basophil count, Basophil percentage increased
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Bilirubin conjugated, Blood alkaline phosphatase, Blood bilirubin increased, Blood chloride normal, Blood creatinine
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Blood glucose normal, Blood potassium, Blood sodium normal, Blood urea, Brain natriuretic peptide
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Carbon dioxide, Dizziness, Eosinophil count, Eosinophil percentage, Erythema of eyelid
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Glomerular filtration rate, Haematocrit, Haemoglobin normal, Lymphocyte count, Lymphocyte percentage
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal, Monocyte count, Monocyte percentage
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Neutrophil count, Neutrophil percentage, Platelet count normal, Red blood cell count normal, Red cell distribution width normal
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Swelling of eyelid, Troponin I, White blood cell count normal
Clinical narrative: cdizziness and lightheadedness, worse with head movements. She mentions having a heaviness sensation in her upper chest and shoulders region. Denies any lip swelling, tongue swelling, shortness of breath, rash, or difficulty swallowing.   lightheadedness, bilateral upper eyelids red and swollen,
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 61.0
Sex: F
Vaccine: COVID19-2
Symptoms: Deafness, Hearing aid user, Hyperacusis, Impaired work ability, Tinnitus
Clinical narrative: A documented mild hearing loss of 12+ years ago left me with hyperacusis, mild intermittent tinnitus (bacon sizzling sounds), and intermittent flares of hearing loss (treated with steroids).  These symptoms have been replaced with more frequent intermittent loss, constant tinnitus and moderate/severe hyperacusis since the third COVID booster in January 2023.  My hearing condition changed within a day of the booster and is listed on my VSAFE account (which I no longer have a chance to access).  I tried a 2-week trial of Widex Hearing Aids to see if the sounds could be adjusted.  The hearing aids rendered no benefit. I cannot access VSAFE information to list specific dates and times. This was my 5th COVID shot (3rd booster)    COVID test positive 12/9/2020 COVID Vaccine - 1/14/2021  Moderna COVID Vaccine - 2/17/2021   Moderna COVID Booster #1 - 11/1/2021   Moderna COVID Booster #2 - 4/20/2022   Moderna COVID test positive - 7/25/2022 COVID Booster #3 - 1/9/2023  Pfizer Bivalent The constant tinnitus is now in a form of white noise/summer insect sounding noise.   The hyperacusis has dramatically increased to the point where I am forced to step back as a pharmacist at the end of July 2023 .  I have suffered increased hyperacusis issues at church listening to certain pitches of voices.  At home, when my family members are talking or eating,  I often leave the room to avoid listening to the crunching issues that are now almost deafening.  Telephone reception sometimes sounds "metallic" in my ears.   I currently have custom-made ear plugs on order from my audiologist.   (I received a telephone call in April 2023 from a CDC representative who encouraged me to file a VAERS report.  I waited to file the report until I could provide updated information on symptoms and treatment.)
Age: 1.0
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 1.08
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 1.0
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: booster dose given instead of primary dose
Age: 0.67
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 0.83
Sex: F
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 0.5
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: given booster dose instead of primary dose
Age: 11.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: given adult vaccine, when shouldve been pediatric
Age: 11.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: 11 year old received adult doses pfizer bivalent vaccine.
Age: 11.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Erythema, Peripheral swelling, Skin warm
Clinical narrative: Redness swelling warm to touch L arm
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: temp and upper arm soreness; temp and upper arm soreness; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received BNT162b2 (BNT162B2), on 15Oct2021 as dose 3 (booster), single (Lot number: FE3590, Expiration Date: 30Nov2021) at the age of 72 years for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, lot number: EN6200), administration date: 27Feb2021, when the patient was 71-year-old, for COVID-19 Immunization, reaction(s): "temp and upper arm soreness", "temp and upper arm soreness"; BNT162b2 (DOSE 2, SINGLE, lot number: ER8730, 9:25AM), administration date: 23Mar2021, when the patient was 72-year-old, for COVID-19 Immunization, reaction(s): "temp and upper arm soreness", "temp and upper arm soreness". The following information was reported: PAIN IN EXTREMITY (non-serious), PYREXIA (non-serious), outcome "unknown" and all described as "temp and upper arm soreness".; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300101946 same patient, different vaccine dose/event;
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: temp and upper arm soreness; temp and upper arm soreness; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received BNT162b2 (BNT162B2), on 15Oct2021 as dose 3 (booster), single (Lot number: FE3590, Expiration Date: 30Nov2021) at the age of 72 years for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, lot number: EN6200), administration date: 27Feb2021, when the patient was 71-year-old, for COVID-19 Immunization, reaction(s): "temp and upper arm soreness", "temp and upper arm soreness"; BNT162b2 (DOSE 2, SINGLE, lot number: ER8730, 9:25AM), administration date: 23Mar2021, when the patient was 72-year-old, for COVID-19 Immunization, reaction(s): "temp and upper arm soreness", "temp and upper arm soreness". The following information was reported: PAIN IN EXTREMITY (non-serious), PYREXIA (non-serious), outcome "unknown" and all described as "temp and upper arm soreness".; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300101946 same patient, different vaccine dose/event;
Sex: U
Vaccine: HPV9
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No symptoms reported/No additional AE/PQC; GARDASIL 9 was administered, but the patient was supposed to receive PREVNAR 20; This spontaneous report was received from a health care professional and referred to a patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 26-JUL-2023, the patient was wrongly vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter, administered for prophylaxis (strength, frequency, anatomical injection site, lot #, expiry date, and route of administration were not provided) (wrong product administered); instead, the subject was supposed to receive pneumococcal vaccine conj 20v (crm197) (PREVNAR 20) 1 dose, (strength, frequency, indication,formulation, lot #, expiry date, and route of administration were not provided). No symptoms were reported and there was no additional adverse event (AE) or product quality complain (PQC).
Age: 29.0
Sex: F
Vaccine: HPV9
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: She received the vaccine today and learned afterward that she is pregnant; No additional AE; This spontaneous prospective pregnancy report has been received from a 29-year-old pregnant female patient, concerning herself.  The patient's medical history, obstetrical history, concurrent conditions, and historical drugs were not provided. Concomitant medications included vitamins Not Otherwise Specified (NOS).   On unknown dates in 2023 (also reported as "this year"), the patient was vaccinated with the 1st and 2nd doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered as Human Papilloma Virus (HPV) prevention (exact doses, lot numbers, expiration dates, routes of administration, and anatomical locations were not provided). On an unspecified date in June 2023, the patient became pregnant (Last menstrual period [LMP] was calculated as an unknown date in June 2023 [reported as "Approximately 4 weeks"], the pregnancy due date was not reported and could not be calculated). On 26-JUL-2023 (also reported as "today"), the patient received the 3rd dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), and learned afterward that she was pregnant (Exposure during pregnancy). No additional information nor adverse event (AE) were reported.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: temp and upper arm soreness; temp and upper arm soreness; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old female patient received BNT162b2 (BNT162B2), on 27Feb2021 as dose 1, single (Lot number: EN6200) at the age of 71 years for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), PYREXIA (non-serious), outcome "unknown" and all described as "temp and upper arm soreness".; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300101946 same patient, different vaccine dose/event;